These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 29479938)

  • 41. Clinical experience of a chronic urticaria referral university center.
    Andrade Coelho Dias G; Cunha Coelho F; Filippo P; Lacerda Pedrazzi D; Nogueira Arraes AC; Perelló MI; Chigres Kuschnir F; Costa E
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):112-120. PubMed ID: 31287262
    [No Abstract]   [Full Text] [Related]  

  • 42. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
    Syrigos N; Grapsa D; Syrigou E
    Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
    Oztop N; Demir S; Unal D; Beyaz S; Terzioglu K; Olgac M; Gelincik A
    Allergy Asthma Proc; 2022 Nov; 43(6):519-528. PubMed ID: 36335414
    [No Abstract]   [Full Text] [Related]  

  • 44. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
    Hide M; Fukunaga A; Suzuki T; Nakamura N; Kimura M; Sasajima T; Kiriyama J; Igarashi A
    Allergol Int; 2023 Apr; 72(2):286-296. PubMed ID: 36272899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
    Syrigos N; Grapsa D; Zande M; Tziotou M; Syrigou E
    Int J Dermatol; 2018 Apr; 57(4):417-422. PubMed ID: 29399789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
    Cubiró X; Spertino J; Rozas-Muñoz E; Serra-Baldrich E; Puig L
    Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria.
    Keskinkaya Z; Kaya Ö; Işık Mermutlu S; Öğretmen Z
    Int Arch Allergy Immunol; 2024; 185(8):786-793. PubMed ID: 38626739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does omalizumab modify a course of recalcitrant chronic spontaneous urticaria?: A retrospective study in Asian patients.
    Kulthanan K; Tuchinda P; Likitwattananurak C; Weerasubpong P; Chularojanamontri L
    J Dermatol; 2018 Jan; 45(1):17-23. PubMed ID: 29044681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
    Mehta H; Bishnoi A; Parsad D; Kumaran MS
    Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
    Eghrari-Sabet J; Sher E; Kavati A; Pilon D; Zhdanava M; Balp MM; Lefebvre P; Ortiz B; Bernstein JA
    Allergy Asthma Proc; 2018 May; 39(3):191-200. PubMed ID: 29458456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study.
    Litovsky J; Hacard F; Tétart F; Boccon-Gibod I; Soria A; Staumont-Sallé D; Doutre MS; Amsler E; Mansard C; Dezoteux F; Darrigade AS; Milpied B; Bernier C; Perrot JL; Raison-Peyron N; Paryl M; Droitcourt C; Demoly P; Grosjean J; Mura T; Du-Thanh A;
    J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3752-3762.e2. PubMed ID: 37652349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.
    Graham J; McBride D; Stull D; Halliday A; Alexopoulos ST; Balp MM; Griffiths M; Agirrezabal I; Zuberbier T; Brennan A
    Pharmacoeconomics; 2016 Aug; 34(8):815-27. PubMed ID: 27209583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
    Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
    Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.